Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Cardiotoxicity 14Breast Neoplasms 11Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma 4Heart Failure 4Prostatic Neoplasms 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia 2Heart Diseases 2Cardiovascular Diseases 2Burkitt Lymphoma 2Ventricular Dysfunction, Left 1Ventricular Dysfunction 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Obesity 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1Mesothelioma 1Memory Disorders 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Echocardiography × Clear all
NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 20 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡